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Advances in immunotherapy are revolutionizing the treatments of certain cancers, especially those in the
blood. However, wider applications for eradicating solid tumors have been slow to emerge. A likely reason
is the presence of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment that secrete
immunosuppressive molecules which attenuate the attack of immune cells. We hypothesize that small
molecule Wnt/Beta- Catenin inhibitors can be used to modulate the immunosuppressive actions of
MDSCs and increase the effectiveness of immunotherapy treatments, such as with chimeric antigen
receptor (CAR)
T-cells. The Wnt/Beta-Catenin Pathway has been shown to be a crucial driving force behind the
immunosuppressive effects exerted by various cells within the tumor microenvironment (TME), including
MDSCs, regulatory T-cells, and cancer cells. Our project goal is to test if inhibitors of the
Wnt/Beta-Catenin Pathway can increase the infiltration, proliferation, and effectiveness of anticancer
immune cells in the TME. To date, we have developed a workflow for identifying lead compounds that
alter the immunosuppressive actions of MDSCs without toxicity to human
T-cells. Peripheral Blood Mononuclear Cells (PBMCs) are isolated from healthy human donors and
differentiated into MDSCs using pro-inflammatory cytokines commonly found within the TME.
Fluorescence Activated Cell Sorting (FACS) and antibody-based magnetic cell sorting are used to
prepare and validate human MDSCs for use in assays. Compounds are tested for toxicity against donor
T-cells to determine non-toxic concentrations for future assays and filter for MDSC specific compounds.
This workflow is now poised to identify novel compounds that modulate the immunosuppressive actions of
MDSCs via Wnt/Beta- Catenin inhibition. This work is part of an ongoing collaboration with the
laboratories of Dr. Steven Katz at the Roger Williams Medical Center and Dr. Jyothi Menon at the
University of Rhode Island.

